A diversified portfolio of biotherapies
Remora Biotech’s portfolio brings cutting-edge research closer to real-world therapies. Each company advances a distinct scientific strategy, supported by our expertise in bioengineering, biological drug design, technology development, and company building.
Miniprotein™ actives
Activen
A Remora Biotech Company
Market: Cosmetics
Segment: Regenerative anti-age
Commercialized
Botulinum neurotoxin booster
Fastox Pharma (exit)
A Remora Biotech Company
Market: Aesthetics & neurology
Segment: Botox®
Acquired by AbbVie in 2024
Antibody-targeted beta-therapy
Atlab Pharma (exit)
A Remora Biotech Company
Market: Radiopharmaceuticals
Segment: Prostate cancer
Acquired by Telix in 2018
Cytokine
Cytune Pharma (exit)
A Remora Biotech Company
Market: Immunotherapy
Segment: Cancer
Acquired by SOTIO in 2018
Innovative cancer target
OGD2 Pharma
A Remora Biotech Company
Market: Immunotherapy
Segment: Pediatric cancer
CAR-T cells
Cellula Therapeutics
A Remora Biotech Company
Market: Cell therapy
Segment: Brain cancer
Targeted cytokines
iMoon Therapeutics
A Remora Biotech Company
Market: Immunotherapy
Segment: Cancer
Multi-checkpoint inhibitors
Nanomunity
A Remora Biotech Company
Market: Immunotherapy
Segment: Cancer
Targeted alpha-therapy
Radiomune Pharma
A Remora Biotech Company
Market: Radiopharmaceuticals
Segment: Cancer
Innovative auto-reactive target
Kalsiom
A Remora Biotech Company
Market: Immunotherapy
Segment: Autoimmunity
Miniprotein™ formulations
The MiniproteinTM Lab
A Remora Biotech Company
Market: Cosmetics
Segment: Regenerative anti-age
Antibody-targeted alpha-therapy
Atonco
Strategic Minority Investment
Market: Radiopharmaceuticals
Segment: Bladder cancer
Microbiota profiling
Byome Labs
Strategic Minority Investment
Market: Cosmetics
Segment: Point-of-care diagnostics